-
-
November 9, 2011 - Alethia Biotherapeutics announces promising in vivo results its EMT inhibitor AB-16B5 and issuance of a patent for the role of secreted clusterin in EMT
-
August 8, 2011 - Alethia Biotherapeutics announces issuance of its second therapeutic target patent stemming from its proprietary target discovery platform
-
June 3, 2011 - Alethia Biotherapeutics announces partnership with Goodwin Biotechnologies for manufacturing of its monoclonal antibody, AB-16B5, an inhibitor of EMT for the treatment of cancer
-
May 26 - Alethia Biotherapeutics announces issuance of its first therapeutic target patent emanating from its proprietary target discovery platform
-
February 10, 2011 - Alethia Biotherapeutics announces the nomination of Mr. Christopher J. Morl to the Board of Directors
-
September 7, 2010 - Alethia Biotherapeutics announces the closing of a $9.6 M financing and the nomination of Dr. William Boyle and Dr. Elizabeth Douville to the Board of Directors
